The costs and reimbursements for lung cancer treatment among selected health care providers in the Czech Republic

Simple item page
dc.contributor.authorŠimrová, Jana
dc.contributor.authorBarták, Miroslav
dc.contributor.authorVojtíšek, Radovan
dc.contributor.authorRogalewicz, Vladimír
dc.contributor.otherEkonomická fakultacs
dc.date.accessioned2014-08-29
dc.date.available2014-08-29
dc.date.defense2014-09-04
dc.description.abstractThe objective of the article is to objectivise and assess the costs for the lung cancer therapy from the payer’s (health insurance company) and the healthcare provider’s (hospital) perspective based on information available from several large hospitals and specialised centres. No comprehensive assessment of costs related to the treatment of lung cancers at all stages has been published in the Czech Republic to-date. The results in this study are calculated based on diagnostic and therapeutic algorithms, i.e. process maps. These, in turn, are derived from the recommended therapeutic procedures issued by the Masaryk Institute of Oncology, the University Hospital in Hradec Králové and the University Hospital in Plzeň. In total, the costs and reimbursements were calculated for 32 utilized algorithms, i.e. process maps. The costs for therapeutic processes account for 22 results, while 10 results correspond to diagnostic processes. Both direct and indirect costs were included in individual calculations. The calculations imply that treatment costs significantly differ depending on the selected diagnostic and therapeutic procedure. It becomes apparent that the setting of the reimbursement system presently generates different stimuli for providers, who may reach both positive and negative balances. This fact, in turn, may have an effect on the economic result leading, in its consequence, to the preference of more suitable alternatives in terms of reimbursement regardless of the optimum procedures for the particular patient. This fact is, to a certain extent, reflected by the reimbursements calculated by means of the DRG system. The given algorithms may potentially be used by health care providers to reach working costs, which will allow accurate calculations for particular hospitals.en
dc.formattext
dc.format.extent74-85 s.cs
dc.identifier.doi10.15240/tul/001/2014-3-007
dc.identifier.eissn2336-5604
dc.identifier.issn12123609
dc.identifier.urihttps://dspace.tul.cz/handle/15240/7088
dc.language.isocs
dc.publisherTechnická Univerzita v Libercics
dc.publisherTechnical university of Liberec, Czech Republicen
dc.publisher.abbreviationTUL
dc.relation.isbasedonZENG, X, et al. The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. PLOS ONE [online]. 2012, Vol. 7, Iss. 10 [cit. 2013-01-11]. Available from: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0048323. ISSN-1932-6203.
dc.relation.isbasedonWOLSTENHOLME, J.L., WHYNES, D.K. The hospital costs of treating lung cancer in the United Kingdom. British Journal of Cancer. 1999, Vol. 80, No. 1-2, pp. 215-218. ISSN 0007-0920.
dc.relation.isbasedonWHO. Cancer. Fact Sheet No. 297 [online]. Copenhagen: WHO, 2013 [cit. 2013-06-06]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
dc.relation.isbasedonVOJTÍŠEK, R., HAVRÁNEK, K., FÍNEK, J. The Use of PET/CT Fusion in Radiotherapy Treatment Planning of Non-Small-Cell Lung Cancers. Klinická Onkologie. 2011, Vol. 24, No. 1, pp. 23-34. ISSN 0862-495X.
dc.relation.isbasedonVOJTÍŠEK, R., FÍNEK, J. Current recommendations for planning radiotherapy for non-small cell lung cancer. Studia Pneumologica et Phthiseologica. 2012, Vol. 72, No. 3, pp. 151-158. ISSN 1213-810X.
dc.relation.isbasedonVERGNENÈGRE, A., MOLINIER, L., et al. The Cost of Lung Cancer Management in France from the Payor’s Perspective. Disease Management & Health Outcomes. 2006, Vol. 14, No. 1, pp. 55-67, ISSN 1173-8790.
dc.relation.isbasedonÚZIS ČR, NOR ČR. Cancer Incidence 2010 in the Czech Republic [online]. Praha: ÚZIS, 2013 [cit. 2013-06-10]. Available from: http://www.uzis.cz/en/publications/cancer-incidence-2010. ISBN 978-80-7472-034-5.
dc.relation.isbasedonSTANISIC, S., BISCHOFF, H.G., et al. Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer. 2010, Vol. 69, No. Suppl. 1, pp. S24-S30. ISSN 0169-5002.
dc.relation.isbasedonŠIMROVÁ, J. Economic analysis of lung cancer therapy. Master Thesis. Kladno: Fakulta biomedicínského inženýrství ČVUT v Praze, 2013. 120 p.
dc.relation.isbasedonSCHILLER, J., TILDEN, D., et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer. 2004, Vol. 43, No. 1, pp. 101-112. ISSN 0169-5002.
dc.relation.isbasedonROGALEWICZ, V., ŠIMROVÁ, J., et al. The Analysis of Costs and Reimbursements for Lung Cancer Treatment in the Czech Republic. Value in Health. 2013, Vol. 16, No. 7. pp. A407. ISSN 1098-3015.
dc.relation.isbasedonPOMPEN, M., GOK, M., et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer. 2009, Vol. 64, No. 1, pp. 110-116. ISSN 0169-5002.
dc.relation.isbasedonPHUNMANEE, A., WIRASORN, K., et al. Lung cancer in hospitalized patients of Thailand. Journal of the Medical Association of Thailand. 2012, Vol. 95, Iss. 7, pp. S201-S205. ISSN 0125-2208.
dc.relation.isbasedonPETERA, J. Guidelines for treatment of small-cell lung cancer: Standard treatment procedure version 2013 [online]. Hradec Králové: Clinic of Oncology and Radiotherapy, University Hospital Hradec Králové, 2013 [cit. 2013-04-30]. 4 p. (PDF). Available from: www.fnhk.cz/fs879/malobunecny-karcinom-plic.pdf.
dc.relation.isbasedonPETERA, J. Guidelines for treatment of non-small-cell lung cancer: Standard treatment procedure version 2013 [online]. Hradec Králové: Clinic of Oncology and Radiotherapy, University Hospital Hradec Králové, 2013. [cit. 2013-04-30]. 10 p. (PDF). Available from: www.fnhk.cz/fs880/nemalobunecny-karcinom-plic.pdf.
dc.relation.isbasedonOECD. Cancer Care: Assuring Quality to Improve Survival. Paris: OECD, 2013. 163 p. ISBN 978-92-64-180963.
dc.relation.isbasedonNRC [online]. Praha: Národní referenční centrum, 2003 [cit. 2013-04-30]. Available from: http://www.nrc.cz/.
dc.relation.isbasedonMOLINIER, L., COMBESCURE, C., et al. Cost of lung cancer – A methodological review. Pharmacoeconomics. 2006, Vol. 24, No. 7, pp. 651-659. ISSN 1170-7690.
dc.relation.isbasedonMAŠKOVÁ, E. Wages and salaries in health services in 2011 [online]. Praha: ÚZIS, Aktuální informace, 2012. Vol. 30 [cit. 2013-02-20]. Available from: http://www.uzis.cz/rychle-informace/mzdy-platy-ve-zdravotnictvi-roce-2011.
dc.relation.isbasedonKUTÍKOVÁ, L., BOWMAN, L., et al. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005, Vol. 50, No. 2, pp. 143-154. ISSN 0169-5002.
dc.relation.isbasedonJOSHI, A.D., CARTER, J.A., et al. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United Kingdom. Clinical Therapeutics. 2011, Vol. 33, No. 3, pp. 291-304.e8. ISSN 0149-2918.
dc.relation.isbasedonHESERAU, D., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Value in Health. 2013, Vol. 16, pp. e1-e5. ISSN 1098-3075.
dc.relation.isbasedonDOLEŽAL, T., PÍSAŘÍKOVÁ, Z., ZEMANOVÁ, P., BARTÁŠKOVÁ, D. Costs of Type II Diabetes in the Conditions of the Czech Republic's Medical Care System. Vnitrni Lek. 2009, Vol. 55, pp. 342-344, ISSN 0042-773X.
dc.relation.isbasedonFERNANDEZ, R.L., et al. Economic burden of cancer Gross the European Union: a population based cost analysis. The Lancet Oncology. 2013, Vol. 14, Iss. 12, pp. 1164-1174. ISSN 1470-2045.
dc.relation.isbasedonDEMOS EUROPA. Towards a sustainable and outcome-driven healthcare: effective healthcare systems at a time of fiscal austerity [online]. V4 Multi-stakeholder Dialogue Warsaw Meeting, Session report, 13-14 December 2011 [cit. 2013-12-15]. Available from: http://www.demoseuropa.eu/index.php?option=com_content&view=article&id=1007:towards-a-sustainable-and-outcome-driven-healthcare&catid=130:2011events&Itemid=155&lang=en.
dc.relation.isbasedonDEDES, K.J., SZUCS, T.D., et al. Management and costs of treating lung cancer patients in a university hospital. Pharmacoeconomics. 2004, Vol. 22, No. 7, pp. 435-444. ISSN 1170-7690.
dc.relation.isbasedonCZECH REUBLIC. Decree No. 475/2012 Coll., which fixes the value of a point, reimbursement limits for covered services, and regulation limits for 2013. Sbírka zákonů. Česká republika 2012, No. 178, pp. 6258-6338. ISSN 1211-1244.
dc.relation.isbasedonCZECH NATIONAL BANK. Central bank exchange rate fixing, 2013 [online]. Praha: ČNB, 2013. [cit. 2013-02-20]. Available from: http://www.cnb.cz/en/.
dc.relation.isbasedonCIPRIANO, L.E., ROMANUS, D., EARLE, C.C., et al. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value in Health. 2011, Vol. 14, No. 1, pp. 41-52. ISSN 1098-3015.
dc.relation.isbasedonČOUPKOVÁ, H. Nemalobuněčný bronchogenní karcinom [online]. Brno: Masaryk Memorial Cancer Institute, 2011 [cit. 2013-02-20]. 11 p. (PDF). Available from: http://www.mou.cz/2-1-nemalobunecny-bronchogenni-karcinom/f76.
dc.relation.isbasedonCHOUAID, C., ATSOU, K., et al. Economics of Treatments for Non-Small Cell Lung Cancer. Pharmacoeconomics. 2009, Vol. 27, No. 2, pp. 113-125. ISSN 1170-7690.
dc.relation.isbasedonCHANG, S., LONG, S.R., et al. Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000. Journal of Clinical Oncology. 2004, Vol. 22, No. 17, pp. 3524-3530. ISSN 0732-183X.
dc.relation.isbasedonBodník [online]. Dan Ohnesorg, 2011 [cit. 2013-02-20]. Available from: http://www.bodnik.cz.
dc.relation.isbasedonBANZ K., BISCHOFF, H., et al. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Lung Cancer. 2011, Vol. 74, No. 3, pp. 529-534. ISSN 0169-5002.
dc.relation.ispartofEkonomie a Managementcs
dc.relation.ispartofEconomics and Managementen
dc.relation.isrefereedtrue
dc.rightsCC BY-NC
dc.subjectcompetitivenessen
dc.subjectsurveyen
dc.subjectcompetitive advantageen
dc.subjectcompetitive strategyen
dc.subject.classificationI12
dc.titleThe costs and reimbursements for lung cancer treatment among selected health care providers in the Czech Republicen
dc.typeArticleen
local.accessopen
local.citation.epage85
local.citation.spage74
local.facultyFaculty of Economics
local.fulltextyes
local.relation.abbreviationE&Men
local.relation.abbreviationE+Mcs
local.relation.issue3
local.relation.volume17
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
EM_03_14_7.pdf
Size:
312.81 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Číslo 3